Home › Trials › NCT06891144

Observational study of older patients with acute myeloid leukemia receiving intensive treatment

Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy

Observational French Innovative Leukemia Organisation · NCT06891144

This study looks at older patients with acute myeloid leukemia to see how well intensive treatment works for them and what factors might affect their recovery and survival.

Quick facts

Study typeObservational
Enrollment1000 (estimated)
Ages60 Years and up
SexAll
SponsorFrench Innovative Leukemia Organisation Academic / other
Drugs / interventionschemotherapy
Locations27 sites (Angers and 26 other locations)
Trial IDNCT06891144 on ClinicalTrials.gov

What this trial studies

This observational epidemiological study focuses on patients aged 60 and over who are diagnosed with de novo or secondary acute myeloid leukemia (AML) and are eligible for intensive induction therapy. The study aims to gather data on the clinical and biological characteristics of these patients and correlate these factors with their treatment outcomes. Given the increasing incidence of AML with age, particularly after 50, the study seeks to understand the effectiveness of intensive chemotherapy in achieving complete remission and the long-term survival rates in this demographic. The research will involve collecting data from multiple centers to provide a comprehensive overview of this patient population.

Who should consider this trial

Good fit: Ideal candidates for this study are patients aged 60 and over with untreated de novo or secondary AML who are suitable for intensive treatment.

Not a fit: Patients with acute myeloid leukemia type 3 or those with severe uncontrolled infections or psychiatric disorders may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of AML in older patients and improve treatment strategies, potentially leading to better outcomes.

How similar studies have performed: While there have been studies on AML treatment in older populations, this specific observational approach focusing on epidemiological characteristics is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients aged 60 and over
* Patients with previously untreated de novo or secondary AML
* Patients suitable for standard intensive treatment
* Patients who have read the information document and agreed to the collection of data concerning them (signature of informed consent).

Exclusion Criteria:

* Patients with AML 3
* Patients with severe, uncontrolled infection at the time of inclusion
* Patients with psychiatric or social disorders that will prevent compliance with the protocol
* Patients without health insurance (affiliation to a social security scheme)

Where this trial is running

Angers and 26 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions AML, Adult
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.